Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May 14:7:F1000 Faculty Rev-575.
doi: 10.12688/f1000research.13926.1. eCollection 2018.

Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations

Kate Skolnik  1 , Bradley S Quon  2
Affiliations
Review

Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations

Kate Skolnik et al. F1000Res. .

Abstract

Pulmonary exacerbations are common events in cystic fibrosis and have a profound impact on quality of life, morbidity, and mortality. Pulmonary exacerbation outcomes remain poor and a significant proportion of patients fail to recover their baseline lung function despite receiving aggressive treatment with intravenous antibiotics. This focused review provides an update on some of the recent advances that have taken place in our understanding of the epidemiology, pathophysiology, diagnosis, and management of pulmonary exacerbations in cystic fibrosis as well as direction for future study.

Keywords: cystic fibrosis; exacerbations; treatment.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

Figures

Figure 1.
Figure 1.. Outline of pulmonary exacerbation treatment decisions.
CBC, complete blood count; CFRSD-CRISS, Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score; Cr, creatinine; CRP, C-reactive protein; C+S, culture and sensitivity; IV, intravenous; LFT, liver function test; PEx, pulmonary exacerbation.
See this image and copyright information in PMC

References

    1. Cystic Fibrosis Foundation Patient Registry: 2015 Annual Report.Bethesda, Maryland.2016. Cystic Fibrosis Foundation. Reference Source
    1. Sanders DB, Bittner RC, Rosenfeld M, et al. : Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. 2010;182(5):627–32. 10.1164/rccm.200909-1421OC - DOI - PMC - PubMed
    1. Bilton D, Canny G, Conway S, et al. : Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. 2011;10(Suppl 2):S79–81. 10.1016/S1569-1993(11)60012-X - DOI - PubMed
    1. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, et al. : Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. 2009;30(3):256–68. 10.1016/j.cct.2009.01.003 - DOI - PMC - PubMed
    1. Sanders DB, Solomon GM, Beckett VV, et al. : Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. 2017;16(5):592–9. 10.1016/j.jcf.2017.04.005 - DOI - PMC - PubMed

    2. F1000 Recommendation

LinkOut - more resources